Floatz Rating
B59/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07649304CT.gov AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | — | Not Yet Recruiting | — | — | — |
NCT07502872CT.gov TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06649812CT.gov Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06765317CT.gov A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05653271CT.gov ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT04914741CT.gov A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | — | Active Not Recruiting | — | — | — |
NCT04231877CT.gov Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · High Grade B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | National Cancer Institute (NCI) | P2 | B · 59 |
| Isocyclophosphamide | University of California, Davis | P3 | BB |
| Etoposide | University of Washington | P3 | BB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | BB |
| Prednisone | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Axicabtagene Ciloleucel | AIDS Malignancy Consortium | P2 | BB |
| Dexasone | University of California, Davis | P2 | BB |
| Rituximab | National Cancer Institute (NCI) | P3 | BB |
+42 more in the High Grade B-Cell Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in High Grade B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-high-grade-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →